OR
Oryzon Genomics S.A.
ORYZF · OTC
$3.31 +0.00% (+$0.00)
1M +1.22%
Market Cap 235.1M €
P/E Ratio -
Div. Yield -
ROE 2.16%
Bulios Fair Price
$2.97
10.3% downside
Current Price
$3.31
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ORYZF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
44 /100
Fair P/S 27.05x
P/B 1.96x
P/E N/A
Growth
96 /100
Growing Book val. growth 13.25%
EPS growth N/A
FCF growth N/A
Profitability
22 /100
Weak Gross margin 96.48%
FCF margin 0.00%
Net margin 27.11%
Quality
1 /100
Poor ROIC 1.43%
Asset turnover 0.06x
ROE 2.16%
Debt
65 /100
Moderate Debt/Equity 0.05x
Int. coverage -14.46x
Current ratio 1.60x
Stability
42 /100
Moderate Beta 0.45x
Profitable years 0
Rev. volatility 45.36%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ORYZF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carlos Manuel Buesa Arjol
Employees
46
Headquarters
Cornellà de Llobregat
Upcoming events
22 OCT
Earnings
Upcoming earnings report